Smart Immune

Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted...

Biotechnology,cell therapy,car t,immuno-oncology,nk cells,t cells,immune reconstitution,t cell progenitors,lymphoid progenitors,naive cells,hsc differentiation,and thymic selection

Smart immune operates in the Biotechnology research industry.

Smart immune's revenue is 11m - 100m

Smart immune has 11 - 50 employees.